Recent Earnings 8-K events
Recent 8-Ks about earnings releases, operating results, guidance, and financial updates.
-
Ashford Trust Q3 2026 earnings release text truncated; no revenue, RevPAR or EPS figures in filing
-
Actelis Q3 2026 revenue up 68% to $1.1M, gross margin 40%, net loss narrowed 37% to $1.2M
-
Sanuwave Q3 2026 revenue falls 24% to $8.6M; operating loss $1.1M on CMS 97610 uncertainty
-
Cumberland posts Q3 net income of $77.8M on Apotex divestiture gain; plans ifetroban NDA in DMD
-
Eastern Q3 2026 net sales up 36% to $75.0M; net income $3.4M ($0.57/sh) vs $0.6M ($0.10)
-
Dolphin Entertainment Q3 revenue up 8.3% to record $16.0M; swings to $0.2M net income
-
Gossamer Bio files first NDA for seralutinib in PAH; Q3 net loss $48.1M, cash $51.2M
-
Azenta FY26 revenue $622M, up 5%; GAAP EPS -$3.50 on $149M impairment; FY27 revenue guided $648-660M
-
Hyliion Q3 revenue jumps to $7.5M from $0.8M; FY2026 guidance raised to ~$18M
-
Tandy Leather Q3 2026 revenue up 7.3% to $18.5M; net income $0.5M vs $1.4M loss
-
KORU Medical Q3 revenue $11.6M, up 11%; net income $0.2M, second straight positive quarter
-
Evolution Petroleum posts FQ1 net loss of $3.0M (-$0.08/sh) on $22.6M revenue; keeps $0.12 dividend
-
iBio Q1 FY2027 revenue rises to $1.1M; IBIO-600 SAD dosing complete, IBIO-610 IND due end-2026
-
Datacentrex Q3 2026 revenue falls 29% but Adjusted EBITDA turns positive at $1.3 million
-
Angel Studios Q3 revenue $159.0M, up 107.7% YoY; net loss narrowed to $5.2M
-
Stran & Co Q3 sales $28.1M (+8.2%), gross margin 33.3%; nine-month net income $1.1M vs $1.0M loss
-
Fortitude Gold Q3 2026: net income $2.0M ($0.07/sh) on $10.3M sales; 2,139 oz produced
-
Meridian Holdings Q3 revenue falls 3% to $46.0M; net loss $13.3M on $11.5M impairments
-
Elevance Health reaffirms 2026 EPS guidance of at least $22.00 and adjusted EPS of at least $29.00
-
Amprius Q3 revenue $39.1M, up 83% YoY; raises 2026 revenue outlook to $145M
-
QuickLogic Q3 revenue $5.1M, up 153% YoY; net loss narrows to $2.2M
-
Inhibikase Q3 2026 net loss $20.5M; cash $193.3M to fund IMPROVE-PAH through Part B readout
-
Biomea Q3 net loss narrows to $6.2M; cash of $26.8M funds runway into Q2 2027
-
StubHub Q3 revenue $502M, adjusted EBITDA $124M; raises FY GMS outlook; CFO James to exit
-
Context Therapeutics Q3 net loss $7.6M; CTIM-76 shows 22% ORR in PROC at weekly doses
-
Palisade Bio Q3 net loss widens to $14.6M; ASCENTRA-UC dosing underway, topline set for Q4 2027
-
Seer Q3 revenue $4.0M, down 3% YoY; FY26 guidance cut to $13.5-$14.5M from $16-$18M
-
Swarmer Q3 revenue falls to $25,554, net loss widens to $9.3M; Ratel UGV deal nears close
-
Marchex Q3 revenue rises to $16.0M; net income $1.3M as adjusted EBITDA hits $2.4M
-
Astronics Q3 2026 sales rise 28.5% to record $271.7M; net income $52.2M, EPS $1.08
-
BBOT Q3 net loss $34.2M; BBO-8520 combo ORR 75% at 500mg in G12C-experienced NSCLC
-
PetMeds Q2 net sales fall 19.4% to $35.8M; net loss narrows to $6.4M ($0.31/sh)
-
Suja Life Q3 sales up 3.3% to $76.4M; adjusted EBITDA $10.5M, net loss narrows to $8.3M
-
Spire Global Q3 2026 revenue $18.0M, up 42% YoY; net loss $20.3M
-
Core & Main prelim Q3 sales $2.12-2.13B; FY26 EBITDA outlook narrowed to $950-960M
-
Netlist Q3 2026 sales jump 149% to $105.1M on $44.9M Samsung license revenue; net income $85.4M
-
Reed's Q3 2026 net sales fall to $6.5M; net loss narrows to $3.2M as gross margin rises to 25%
-
Altaba reports Sept 30 NAV of $1.74/share; net assets $906M, investments $467M
-
BrightView Q4 revenue falls 3.6% to $677.3M; introduces FY2027 revenue and EBITDA guidance
-
RideNow Q3 revenue falls 13.1% to $244.3M; net loss widens to $13.9M, adjusted EBITDA $5.3M